Temisis Therapeutics
Created in 2018
- BETA
To investigate (B)
Some signals may appear as inconsistent with a regular activity Social networks
394Activities
Technologies
Entity types
Location
19 Av. de la Forêt de Haye, 54500 Vandœuvre-lès-Nancy, France
Vandœuvre-lès-Nancy
France
Employees
Scale: 2-10
Estimated: 2
Engaged corporates
4
2 3Added in Motherbase
8 months, 4 weeks ago
biotech Value proposition
Biotech developing novel first-in-class small-molecules to treat immuno-inflammatory diseases with high unmet needs
“Temisis Therapeutics ("Temisis") is a pre-clinical stage biotechnology company developing innovative drugs derived from natural sources for the treatment of auto-immune and chronic inflammatory diseases, with an initial focus on psoriasis.
Temisis most advanced compound, TEM-1657, a first-in-class and orally bioavailable small molecule, has demonstrated highly promising preclinical efficacy and safety profile in animal model of psoriasis, superior to Apremilast (Otezla TM), a Standard of Care (SOC) for patients with mild to moderate plaque psoriasis. In addition, TEM-1657 exhibited strong protective effect against Ulcerative Colitis (UC) in rodent, a form of Inflammatory Bowel Disease (IBD), which indicates this compound has therapeutic potential for other autoimmune/inflammatory diseases. TEM-1657 and its analogues act through a novel and breakthrough mechanism of action (MoA) downmodulating the release of key proinflammatory cytokines.
Founded in December 2017, Temisis is based in Nancy and is a subsidiary of Plant Advanced Technologies ("PAT"), a plant-based biotechnology company specialized in the discovery and eco-friendly production of hard-to-source plant active extracts for the cosmetic, nutraceutical, agro-chemical and biotechnology markets.”
biotechnology, dermatology, and semi-synthesisOriginal language
Biotech developing novel first-in-class small-molecules to treat immuno-inflammatory diseases with high unmet needs
“Temisis Therapeutics ("Temisis") is a pre-clinical stage biotechnology company developing innovative drugs derived from natural sources for the treatment of auto-immune and chronic inflammatory diseases, with an initial focus on psoriasis.
Temisis most advanced compound, TEM-1657, a first-in-class and orally bioavailable small molecule, has demonstrated highly promising preclinical efficacy and safety profile in animal model of psoriasis, superior to Apremilast (Otezla TM), a Standard of Care (SOC) for patients with mild to moderate plaque psoriasis. In addition, TEM-1657 exhibited strong protective effect against Ulcerative Colitis (UC) in rodent, a form of Inflammatory Bowel Disease (IBD), which indicates this compound has therapeutic potential for other autoimmune/inflammatory diseases. TEM-1657 and its analogues act through a novel and breakthrough mechanism of action (MoA) downmodulating the release of key proinflammatory cytokines.
Founded in December 2017, Temisis is based in Nancy and is a subsidiary of Plant Advanced Technologies ("PAT"), a plant-based biotechnology company specialized in the discovery and eco-friendly production of hard-to-source plant active extracts for the cosmetic, nutraceutical, agro-chemical and biotechnology markets.”
Home - Temisis Therapeutics Focused on the development of novel and highly efficacious drugs for the treatment of inflammatory diseases
https://www.temisis.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Communauté Urbaine du Grand Nancy National and local authorities, Government Administration | Communauté Urbaine du Grand Nancy National and local authorities, Government Administration | Other 31 Aug 2023 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 22 Sep 2023 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 31 Jan 2023 | | |
 BioValley France Public business cluster, Biotechnology, French Cluster, Biotechnology Research | BioValley France Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 31 Jan 2023 | | |